ArticleBMC infectious diseases2007
In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections.
Article in BMC infectious diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Antibiotic synergy againstAntimicrobial agents and chemotherapy · 2025Pooled it
- Trial
- Antimicrobial resistance in veterinary medicine: Mechanisms, regulation and control strategies.Veterinarni medicina · 2026Review
- Synergistic interactions of ruthenium-based carbon monoxide-releasing molecules and antibiotics in their effects onMicrobiology (Reading, England) · 2026Article
- Antibacterial Activity of the Vancomycin and Cefotaxime-Incorporated Total Etch Adhesive System - AnJournal of pharmacy & bioallied sciences · 2024Article
- Characterization of Novel LyticPharmaceuticals (Basel, Switzerland) · 2022Article
- Cocktail of isobavachalcone and curcumin enhance eradication ofFrontiers in microbiology · 2022Article
- GMI, an Immunomodulatory Peptide fromInternational journal of molecular sciences · 2021Article
- Synergistic efficacies of thymoquinone and standard antibiotics against multi-drug resistant isolates.Saudi medical journal · 2021Article
- Ceftobripole: Experience in staphylococcal bacteremia.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019Review
- Curcumin nanoparticles are a promising anti-bacterial and anti-inflammatory agent for treating periprosthetic joint infections.International journal of nanomedicine · 2019Article
- In Vitro activity of novel glycopolymer against clinical isolates of multidrug-resistant Staphylococcus aureus.PloS one · 2018Article
- msaABCR operon is involved in persister cell formation in Staphylococcus aureus.BMC microbiology · 2017Article
- Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus.The Journal of antibiotics · 2017Article
- Skin Immune Landscape: Inside and Outside the Organism.Mediators of inflammation · 2017Review
- Article
- (1)H, (15)N, and (13)C resonance assignments of Staphylococcus aureus extracellular adherence protein domain 4.Biomolecular NMR assignments · 2016Article
- Inhibition of LpxC Increases Antibiotic Susceptibility in Acinetobacter baumannii.Antimicrobial agents and chemotherapy · 2016Article
- Luteolin potentiates the effects of aminoglycoside and β-lactam antibiotics against methicillin-resistantExperimental and therapeutic medicine · 2016Article
- Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethicillin resistant Staphylococcus aureus (MRSA) is an increasingly common cause of nosocomial infections, causing severe morbidity and mortality worldwide, and accounting in some hospitals for more than 50% of all S. aureus diseases. Treatment of infections caused by resistant bacterial pathogens mainly relies on two therapeutic modalities: development of new antimicrobials and use of combinations of available antibiotics. Combinations of antibiotics used in the empiric treatment of infections with suspected methicillin resistant Staphylococcus aureus etiology were investigated.
methodsDouble (vancomycin or teicoplanin with either levofloxacin or cefotaxime) and triple (vancomycin or teicoplanin + levofloxacin + one among amikacin, ceftazidime, cefepime, imipenem, piperacillin/tazobactam) combinations were evaluated by means of checkerboard assay and time kill curves. Mutational rates of single and combined drugs at antimicrobial concentrations equal to the resistance breakpoints were also calculated.
resultsVancomycin or teicoplanin + levofloxacin showed synergy in 16/50 and in 9/50 strains respectively, while vancomycin or teicoplanin + cefotaxime resulted synergic for 43/50 and 23/50 strains, respectively. Triple combinations, involving teicoplanin, levofloxacin and ceftazidime or piperacillin/tazobactam gave synergy in 20/25 strains. Teicoplanin + levofloxacin gave synergy in triple combinations more frequently than vancomycin + levofloxacin. For single antibiotics, mutational frequencies ranged between 10(-5) and <10(-9) for levofloxacin, cefotaxime, amikacin and imipenem, and <10(-9) for vancomycin and teicoplanin. When tested in combinations, mutational frequencies fell below 10(-9) for all the combinations.
conclusionIn vitro evidence of synergy between glycopeptides, fluoroquinolones (levofloxacin) and beta-lactams and of reduction of mutational frequencies by combinations are suggestive for a potential role in empirical therapy of severe pneumonia with suspected MRSA etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.